The CRISPR/Cas9 system is a research hotspot in genome editing and regulation. Currently, it is used in genomic silencing and knock-in experiments as well as transcriptional activation and repression. This versatile system consists of two components: a guide RNA (gRNA) and a Cas9 nuclease. Recognition of a genomic DNA target is mediated through base pairing with a 20-base gRNA. The latter further recruits the Cas9 endonuclease protein to the target site and creates double-stranded breaks in the target DNA. Compared with traditional genome editing directed by DNA-binding protein domains, this short RNA-directed Cas9 endonuclease system is simple and easily programmable. Although this system may have off-target effects and in vivo delivery and immune challenges, researchers have employed this system in vivo to establish disease models, study specific gene functions under certain disease conditions, and correct genomic information for disease treatment. In regards to pain research, the CRISPR/ Cas9 system may act as a novel tool in gene correction therapy for pain-associated hereditary diseases and may be a new approach for RNA-guided transcriptional activation or repression of pain-related genes. In addition, this system is also applied to loss-of-function mutations in pain-related genes and knockin of reporter genes or loxP tags at pain-related genomic loci. The CRISPR/ Cas9 system will likely be carried out widely in both bench work and clinical settings in the pain field.
Introduction
The CRISPR/Cas9 system is becoming increasingly popular in the field of genomic editing and gene regulation. This system was developed based on the RNA-guided Cas9 endonuclease found in bacteria immune system. CRISPR refers to clustered regularly interspaced short palindromic repeats, which are segments of prokaryotic DNA containing short repeats of base sequences. Each repetition is followed by short sequence of "spacer DNA" derived from previous virus intruder genome [1] . Subsequent transcriptions from the CRISPR repeat-spacer units yield two noncoding RNAs: one CRISPR RNA (crRNA) containing nuclease guide sequences compiled from the spacers, and another noncoding RNA, complementary to the repeat sequence, known as trans-activating crRNA (tracrRNA). When a virus invades the bacterium for a second time, this dual crRNA:tracrRNA is now capable of recognizing the viral DNA as foreign, and thus base pairs with the intruder DNA and recruits Cas9 endonuclease to create double strand DNA (dsDNA) breaks at the recognition site, ultimately this leads to silencing of the viral gene [1] [2] [3] . The CRISPR/Cas9 system is the type II prokaryotic immune system, which provides acquired cent motif (PAM) sequence at the 5' end [5] (Fig. 1) . To improve the efficiency of the CRISPR/Cas9 system in genome editing, recent studies designed single chimeric guide RNA (sgRNA) molecules. These molecules contain a target recognition 20-base RNA sequence mimicking the function of crRNA, followed by a hairpin scaffold structure mimicking the base-pairing interactions between tracrRNA and crRNA [3] (Fig. 1) . Once dsDNA breaks are achieved in the targeted gene, cells activate their error-prone non-homologous end joining repair (NHEJ) pathways to fix the damage, resulting in random insertion/deletion mutations (indels) of DNA bases at the cut site. Introduction of indels to the coding frame of the targeted gene consequently leads to changes in the target gene expression including genetic knockdown [5] (Fig. 2 ). If a homologous DNA template is provided, cells repair their DNA through homologous recombination, resulting in genomic knock-in at the specific cut site ( Fig. 2) . Thus, the CRIPSR/Cas9 system can be used in mammalian genomic editing including the production of knockout or knockin models.
Genomic Editing
Disruption of a target gene is a way to decipher the function of a gene. As discussed above (Fig. 2 ), by using the CRIPSR/Cas9 system, genomic editing can be achieved by creating a single gRNA directed toward the gene of interest that will recruit a Cas9 endonuclease. This versatile system has been carried out to disrupt several genes in order to decipher their functions [6] or to provide a potential gene correction therapy in mammals [7, 8] . For example, the disruption of CDK11 was achieved in an osteosarcoma cell line using the CRIS-PR/Cas9 system, resulting in decreases in cell proliferation and viability [6] . The human pcsk9 (proprotein convertase subtilisin/kexin type 9) gene has emerged as a promising therapeutic target for cardiovascular disease, given that individuals with naturally occurring loss-of-function pcsk9 mutations experience reduced low-density lipoprotein cholesterol levels which protects against cardiovascular disease. Achieving loss of function mutations in the Pcsk9 gene using the CRIS-PR/Cas9 system successfully decreased serum PCSK9 by 90% and total cholesterol levels by 40% in a mouse model [7, 9] . Moreover, by introducing multiple gRNAs simultaneously, this system could easily be adapted to target multiple genes at the same time. This may be im-immunity through gaining resistance to foreign genetic elements [1] . By delivering the Cas9 endonuclease and appropriate guide RNAs into mammalian system, genome editing in mammalian cells could be efficiently performed.
Cas9 is an endonuclease with two enzymatic domains: an HNH domain that cleaves the complementary strand of DNA that base pairs with the guide RNA and an RuvC1 domain that cleaves the noncomplementary strand [4] (Fig. 1 ). The RNA-guided Cas9 system will only recognize its target sequence if that target sequence is immediately followed by a protospacer-adja- portant for studying the effects of a family of proteins or a pathway on behaviors. The role of DNA methylation in the development of human embryonic stem cells was investigated through successful co-knockout of the three key DNA methyltransferase enzymes, DNMT1, DNMT3a and DNMT3b by co-application of three gRNAs targeting each enzyme [10] . Commercially available CRISPR gRNA libraries offer a convenient approach to achieve large-scale loss-of-functionbased screening in different species. By knocking out thousands of genes individually using a genome-scale mouse CRISPR gRNA library in a non-metastatic cancer model, the top metastatic cancer contributors were dissected [11] . Another gRNA library targeting 19,150 mouse protein-coding genes was designed to reveal their roles in drug resistance [12] .
The CRISPR/Cas9 system has also been used for specific gene knockin studies. As described in Figure 2 , the cut at the locus of interest is induced by gRNA-directed Cas9 endonuclease. When a DNA cassette flanked by homology arms is provided as a donor template, the cut site is repaired through homologous recombination and the template is incorporated into the selective DNA cassette [13] (Fig. 2 ). Since the CRISPR targeting site is destroyed by gene insertion, this CRISPR-Cas9 system is mostly carried out to enable reporter gene knockin for the identification and purification of specific cell types of interest. With the use of this system, researchers have successfully generated mice carrying V5 tags, mCherry or GFP fluorescence reporters at the 3' ends of target genes or insertion of two loxP sites flanking an exon of a target gene [14] . Similar engineering was also carried out in rats to obtain reporter knockin and floxed alleles [15, 16] . The principles established in these studies could directly apply to other species for simplifying the genome engineering process.
Finally, the CRISPR/Cas9 system has been employed in transcription regulation. The gRNA-mediated recruitment of a cleavage inactive form of Cas9 [dead Cas9 (dCas9), D10A mutant in RuvC1 domain and H841A mutant in HNH domain] enables the gR-NA-dCas9 complex to harbor specific regulatory positions of a given gene, acting as a scaffold to recruit transcriptional regulators and interfere with transcriptional elongation, RNA polymerase binding or transcription factor binding, resulting in alternations in the expression of target genes [17] . Fusion of dCas9 with a transcriptional repressor domain robustly silences the endogenous target genes. For example, dCas9 has been fused to KRAB (Krüppel-associated box, a category of repressive chromatin modifier domains) [18] , which resulted in transcription repression (Fig. 3) . In contrast, dCas9 can be converted into an RNA-guided transcription activator (dCas9-activator) when fused to transcriptional activation domains [19, 20] , as in the case of dCas9-VP64 (virus protein 64, tetrameric virus protein 16 transcription activator domain) ( Fig. 4) . In order to obtain highly specific and efficient transcriptional regulation, the design of the fusion protein or fusion partner is key for future optimization efforts. (TALE) DNA binding domain, consisting of ~ 500-700 amino acids, and also one non-specific DNA cleavage domain [28] [29] [30] (Fig.5B ). Based on the already deciphered DNA:protein binding codes [31, 32] , TALE domain now can be designed to recognize almost any desired sequence.
However, both nuclease domains in ZFN and TALEN systems recognize their genomic targets by amino acid sequence in the DNA binding domain of either zinc finger protein or TALE protein (protein-DNA interaction), which means the amino acid sequence of their DBD has to be redesigned for each target site, which can be a painstakingly lengthy process. In contrast, Cas9 endonuclease-mediated dsDNA breaks only require co-expression of a single target-specific guide RNA. The specificity of ZFN and TALEN can be enhanced by increasing the number of zinc finger or TALE modules [33] , whereas the specificity of CRISPR-Cas9 is dependent on a 20 bp guide RNA. Moreover, since the targeting specificity of ZFN and TALEN is defined solely by protein-DNA interactions, their off-targets are context-dependent and cannot be completely predicted based on the DNA sequence homology. On the contrary, CRISPR-Cas9 recognizes targets based on Watson-Crick basepairing rules. Therefore, the off-target sites in the CRISPR-Cas9 system can be more reliably predicted based on sequence homology. Taken togeth-
Advantages over Other Methods
Currently, ZFN, TALEN and CRISPR/Cas9 system, comprise a powerful class of tools for genomic engineering. Zinc finger nucleuses are artificial chimeric site-specific endonuclease engineered by fusing a zinc finger DNA-binding domain to a non-specific DNA-cleavage domain of the restriction endonuclease FokI [21, 22] . The zinc finger DNA binding domain consists of 3-6 zinc finger units, with each unit recognizing 3 base-pairs of DNA. Since the non-specific nuclease FokI only creates a dsDNA break when it dimerizes, ZFN targets consist of two zinc-finger binding sites separated by a 5-7-bp spacer sequence recognized by the FokI cleavage domain (Fig. 5A ). Once the cut is achieved, the NHEJ pathway takes place and results in loss of gene function [21, 22] . However, the various zinc finger units when assembled in arrays interfere with each other, resulting in decreased efficiency in binding the DNA targets [23, 24] . With the necessity of dimerization of the system, the ZFN system has accessible targets approximately every 500 basepairs of random genomic sequence [25, 26] , while CRISPR/Cas9 has a targeting range of 1 in every 8 basepairs of random genomic sequence [27] . Due to this limitation in the sequences recognized by ZFNs, the improved artificial nuclease TALEN, similar to ZFN, was introduced. TALEN is composed of one transcription-like effector er, compared to the traditional genome editing tools, the CRISPR/Cas9 system has several advantages including simplicity in target design, genome-wide accessibility, the ability to target multiple sites in one step, and predictable off-target effects.
Prospective applications in pain research and treatments.
Based on the characteristics of the CRIPSR/Cas9 system in genomic editing and its advantages over traditional genomic editing strategies described above, it is expected that this system may have potential applications in the generation of pain-related transgenic animals, the exploration of chronic pain mechanisms, and the treatment of pain-associated congenital diseases.
Genetically modified mice created using various transgenic technologies have been widely used in preclinical pain research. Conventional or congenital genetic KO mice have been generated through gene targeting with homology recombination in embryonic stem cells [34] . Using this approach, researchers have studied the functions of a pain-related gene in vivo. However, given that the gene is deleted from conception, this model has several limitations. As a whole-body KO, this model lacks the ability to identify tissue-specific effects of gene deficiency. Some gene KO strains die in early developmental stages and this prevents researchers from studying the function of these genes through adulthood. Moreover, knocking out a target gene during the embryonic period may result in compensatory changes in the expression of other genes or non-specific changes during the development that may affect animal behaviors [35, 36] . The generation of conditional genetic KO mice with spatial and temporal control of gene inactivation using the Cre-loxP system may avoid these limitations. However, the fertility rate of tamoxifen-inducible Advillin-Cre-ERT2 recombinase mice [37] that are presently available for studying the role of individual genes in adult sensory neuron function is rather low (personal communications with Dr. John N Wood's Lab). In addition, other genetically modified animals (except for transgenic mice) are unavailable because germline-competent embryonic stem cells were achieved only in mice. The CRISPR/Cas9 system may overcome the limitations caused by these traditional transgenic technologies. This system is able to create both germ-line and somatic animal models with point mutations, deletions and complex chromosomal rearrangements [38] . Indeed, recent researchers have carried out the easily programmable CRISPR/Cas9 system to generate genetically modified mouse and rat lines [14] [15] [16] . The principles established in these studies could directly be applied to pain-related genes. In addition, given that the CRISPR/Cas9 system is simple in target design and has wide genome accessibility and predictable off-target effects, genome engineering using this system could be less time consuming.
Chronic pain is an unpleasant, long-term sensory and emotional experience that affects millions of people worldwide. Unsatisfactory effective treatment for this disorder is partially due to a lack of knowledge concerning the molecular mechanisms that underlie chronic pain development and maintenance. In the past decades, several pathophysiological mechanisms have been proposed. For example, peripheral nerve injury-induced abnormal ectopic firing in the neuroma at the injured site and dorsal root ganglion neurons is thought to contribute to nerve injury-induced pain hypersensitivity [39] [40] [41] [42] . The occurrence of such ectopic firing may be related to the reduced expression of some voltage-gated potassium channels (Kvs) such as Kv1.2 in DRG [43] [44] [45] [46] . In addition, the expression of opioid receptors in the injured dorsal root ganglion (DRG) significantly decreased following peripheral nerve injury. This decrease not only results in reduced opioid analgesia in neuropathic pain management, but also enhanced release of neurotransmitters in primary afferents which participates in neuropathic pain genesis [47, 48] . Thus, rescuing the reduction in these receptors and/or channels may attenuate the development and maintenance of neuropathic pain [43] . Using the CRISPR/Cas9 system, designing a sequence specific guide RNA targeting the genes encoding opioid receptors and voltage-gated potassium channels (e.g., Kv1.2), combined with an RNA-guided nuclease-deficient Cas9 (dCas9) protein fused with transcriptional activators, could rescue the reductions of these pain-related genes through their enhanced transcription and alleviate nerve injury-induced pain hypersensitivity. Thus, the application of the CRISPR/Cas9 system not only further elucidates the mechanisms underlying chronic pain but also can be used as a complementary strategy for pharmacolog-ical drugs in the treatment of this disorder.
Patients with some congenital diseases display sensory changes that alter their perception of pain. Cohorts of patients suffer from hereditary sensory and autonomic neuropathies (HSAN) that result in a marked absence of pain sensitivity [49] . These patients lack itch sensations, deep pain sensations in bones and joints and, most importantly, the protective reflexes induced by pain perception [50] . HSAN type IV is linked to mutations in the gene encoding for the tropomyosin receptor kinase A, a nerve growth factor (NGF) receptor [51] , whereas HSAN type V is associated with a mutation in the NGF gene [52] . Loss-of-function mutations in the SCN9A gene that encode voltage-gated sodium channel Nav1.7 result in congenital insensitivity to pain in humans and mice [53, 54] . Gain-of-function mutations in the SCN9A gene result in spontaneous pain as observed in paroxysmal extreme pain disorder and primary erythermalgia [55] [56] [57] . Gain-of-function mutations in the SCN10A gene that encode voltage-gated sodium channel Nav1.8 also result in painful peripheral neuropathy [58] . Gain-of-function mutations in the SCN11A gene that encodes voltage-gated sodium channel Nav1.9 cause painful neuropathy [59] [60] [61] or insensitivity to pain [62, 63] depending on the site and content being mutated. Therefore, the CRISPR/Cas9-meidiated homology directed repair systems guided by specific guide RNAs targeting these mutated genes may provide in vivo gene correction therapy for these congenital diseases.
Future challenges in the application
The CRISPR/Cas9 system has been used intensively in in vitro experiments, but its application in in vivo studies may have several challenges including off-target effects, in vivo delivery vectors, and immune responses.
Off-target effects of the CRISPR-Cas9 system usually result from mismatches between the 20-base guide RNA and its target DNA sequence. Of note, multiple mismatches could be tolerated depending on the quantity, position and base identity of mismatches. For example, within the 20-base guide RNA, mismatches are less tolerated in the second half because the second half recognizes the seed region (6-11 bp upstream of PAM) in the targeted DNA sequence, leading to more off-target effects [3, 5] . Efforts have been made to minimize the CRISPR-Cas9's off-target effects. Cho et al. reported that, by modifying guide RNA and Cas9, the system could effectively discriminate on-target sites from off-target sites [64] . Dual crRNA-tracrRNA rather than single chimeric guide RNA or the use of synthetic guide RNA instead of guide-RNA coding plasmids also help alleviate off-target effects [64] . The utility of single or dual Cas9 nickase could also significantly reduce off-target effects. In gain-of-function research, the utility of a mutant variant of Cas9 nickase (D10A in its RuvC I domain) that creates only single stranded breaks could significantly reduce off-target effects as nicked DNA tends to be repaired by high-fidelity homologous recombination [8, 13, 64] . In loss-of-function studies, implementation of dual Cas9 nickases on opposite DNA strands with separate guide RNAs leads to efficient dsDNA break formation with 50-to 1500-fold fewer off-target insertions or deletions [65] .
The viral vectors that express the CRISPR/Cas9 system for in vivo delivery may have safety concerns, limited packaging capacities, and limitations in the infected cell types. Although adenoviral, adeno-associated viral (AAV), and lentiviral vectors have been applied for delivery of the CRISPR/Cas9 system in vivo [12, 66, 67] , AAV vectors are the most promising in vivo vehicles because they have little immunogenic potential or endogenous vector recombination [68] and a broad range of serotype specificity [69, 70] . Additionally, the restrictive ~4.5 kb cargo size of AAV vectors could be overcome by packaging of a smaller-sized Staphylococcus aureus Cas9 (SaCas9) orthologue instead of the 4.2 kb S. pyogenes Cas9 (SpCas9) nuclease [9] . Recent advances in non-viral vehicles make them potential alternatives for CRISPR/Cas9 delivery. Compared with viral vectors, non-viral vehicles do not have viral safety concerns, and are generally easier to be synthesized or produced [71] . One such non-viral vehicle, a nanoparticle named "7C1", has been used for in vivo delivery of guide RNA in Cre-dependent and constitutive Cas9-expressing mice [72] . Further optimization in in vivo delivery vehicles will provide a potential use of the CRIS-PR/Cas9 system in translational research.
A recent study reported that Cas9 as a foreign bacterial protein led to an immune response in mammals [73] . Upon Cas9 protein stimulation in mice, Cas9-specific antibody was generated and interleukin-2 secreted from the Cas9-primed splenocytes [73] . Therefore, further
